Precision Obesity Treatments Including Pharmacogenetic and Nutrigenetic Approaches

详细信息    查看全文

• 作者：Maite Solas¹ ; ² ; Fermin I. Milagro³ ; ⁴ ; Diego Mart&iacute ; nez-Urbistondo⁵ ; Maria J. Ramirez¹ ; ² ; J. Alfredo Mart&iacute ; nez² ; ³ ; ⁴ ; ^{jalfmtz@unav.es" class="auth_mail" title="E-mail the corresponding author}
• 关键词：bioactive compounds ; hypocaloric diet ; polymorphism ; personalized nutrition ; weight loss ; food intake
• 刊名：Trends in Pharmacological Sciences
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：37
• 期：7
• 页码：575-593
• 全文大小：2622 K

文摘

Five pharmaceutical strategies are currently approved by the US FDA for the treatment of obesity: orlistat, lorcaserin, liraglutide, phentermine/topiramate, and bupropion/naltrexone. The most effective treatment seems to be the combined administration of phentermine/topiramate followed by lorcaserin and bupropion/naltrexone. In relation to the management of excessive weight, other aspects also need to be considered, including comorbidities accompanying obesity, drug interactions, and the risk of negative collateral effects, as well as individualized treatments based on the genetic make-up. This review aims to provide an overview of the approved anti-obesity drugs and newer molecules that could affect different targets in the central nervous system or peripheral tissues, the molecular mechanisms, emerging dietary treatments and phytogenic compounds, and pharmacogenetic/nutrigenetic approaches for personalized obesity management.